Identifying and treating imatinib failure in chronic myelogenous leukemia: a practical review of treatment guidelines and available agents
Authors:
- Stuart L. GoldbergSGStuart L. Goldberg
- Aisha MasoodAMAisha Masood
- 1 March 2009
- journal article
- review article
- Published by Elsevier in Community Oncology
- Vol. 6 (3) , 113-125
Abstract
No abstract availableThis publication has 80 references indexed in Scilit:
- Translation of the Philadelphia chromosome into therapy for CMLBlood, 2008
- Allogeneic Hematopoietic Progenitor Cell Transplantation for the Treatment of Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors: Lessons Learned to DateClinical Lymphoma Myeloma and Leukemia, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®)versusinterferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemiaLeukemia & Lymphoma, 2007
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003
- The Biology of Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantationThe Lancet, 1998
- Interferon Alfa-2b Combined with Cytarabine versus Interferon Alone in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 1997
- Induction of Chronic Myelogenous Leukemia in Mice by the P210
bcr/abl
Gene of the Philadelphia ChromosomeScience, 1990